Tomer Izraeli
Co-founder & CEO
Claimed by owner Polyrizon
Former names:
Innovative Intranasal Products
Polyrizon
www.globenewswire.com
•
Dec 23, 2021
Medigus: Polyrizon to Test its Product Candidate for Protection Against the Highly Transmissible Corona Virus Omicron Variant
www.globenewswire.com
•
Nov 1, 2021
Medigus: Polyrizon Innovative Technology Demonstrated it may Prevent Allergic Reaction Caused by Common Allergens
www.globenewswire.com
•
Oct 22, 2021
Medigus: Polyrizon to Initiate Processes Towards FDA Submission
newsonlineche.in
•
Jul 23, 2021
https://newsonlineche.in/2021/07/23/polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study/
www.globenewswire.com
•
Nov 9, 2020
Medigus to Invest up to an Additional $150,000 in COVID-19 Protection Biogel Developer Polyrizon
www.spglobal.com
•
Jul 20, 2020
Insight Weekly: Banks' efficiency push;vacuuming carbon;Big Pharma diversity goals
About
Polyrizon is a biotech company focused on the development and commercialization of innovative intranasal products.
Polyrizons Capture & Contain (C&C) platform is based on a natural 3D polymeric network tailored to optimally adhere to the nasal mucosal surface. The polymeric network creates a physical barrier that captures and contains biological contaminants, preventing their penetration. The C&C platform can be readily adapted for a wide range of applications to protect the human body from airborne contaminants such as allergens, viruses, and molds.
The companys Trap & Target (T&T) platform delivery technology is designed to allow a long residence time and intimate contact with the mucosal tissue for highly effective targeted delivery of medicines. It can be tailored to address the specific requirements of different molecules for improved therapeutic effect.
The owner of 35.86% of Polyrizons share capital is Medigus, a technology company engaged in advanced medical solutions, innovative internet technologies, and electric vehicle and charging solutions.
Polyrizons Capture & Contain (C&C) platform is based on a natural 3D polymeric network tailored to optimally adhere to the nasal mucosal surface. The polymeric network creates a physical barrier that captures and contains biological contaminants, preventing their penetration. The C&C platform can be readily adapted for a wide range of applications to protect the human body from airborne contaminants such as allergens, viruses, and molds.
The companys Trap & Target (T&T) platform delivery technology is designed to allow a long residence time and intimate contact with the mucosal tissue for highly effective targeted delivery of medicines. It can be tailored to address the specific requirements of different molecules for improved therapeutic effect.
The owner of 35.86% of Polyrizons share capital is Medigus, a technology company engaged in advanced medical solutions, innovative internet technologies, and electric vehicle and charging solutions.
Employees
Product stage
Primary Sector
Life Sciences & HealthTech
Products
CAPTURE & CONTAIN, TRAP & TARGET
Geographic markets
-
News
(6)
www.globenewswire.com
•
Dec 23, 2021
Medigus: Polyrizon to Test its Product Candidate for Protection Against the Highly Transmissible Corona Virus Omicron Variant
www.globenewswire.com
•
Nov 1, 2021
Medigus: Polyrizon Innovative Technology Demonstrated it may Prevent Allergic Reaction Caused by Common Allergens
www.globenewswire.com
•
Oct 22, 2021
Medigus: Polyrizon to Initiate Processes Towards FDA Submission
newsonlineche.in
•
Jul 23, 2021
https://newsonlineche.in/2021/07/23/polyrizons-innovative-proprietary-technology-found-effective-against-coronavirus-in-a-pre-clinical-study/
www.globenewswire.com
•
Nov 9, 2020
Medigus to Invest up to an Additional $150,000 in COVID-19 Protection Biogel Developer Polyrizon
www.spglobal.com
•
Jul 20, 2020
Insight Weekly: Banks' efficiency push;vacuuming carbon;Big Pharma diversity goals
The Team
(4)
TI
ESR
Eyal S. Ron
CTO
DA
Daphna Avital
Chief People Officer
TT
Tidhar Turgeman
Head of R&D
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Private Equity Funding
Undisclosed Round
$100K
Jul 2020
1 Investors
$100K
Undisclosed Round
$150K
Nov 2020
1 Investors
$150K
Others
Academic Techonology
Jan 2005
undefined
Protective biological-gels as a physical/chemical barrier to pathogens
Media gallery
(0)Locations
Israel
HaTidhar St 5, Ra'anana, Israel
Locations
Israel
HaTidhar St 5, Ra'anana, Israel
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,